Nu Skin Enterprises (NUS) Financials

$6.31 +0.03 (+0.49%)

As of 09:53 AM Eastern

Annual Income Statements for Nu Skin Enterprises

This table shows Nu Skin Enterprises' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	105	8.60	-147
Consolidated Net Income / (Loss)	105	8.60	-147
Net Income / (Loss) Continuing Operations	105	8.60	-147
Total Pre-Tax Income	89	27	-175
Total Operating Income	111	48	-152
Total Gross Profit	1,595	1,357	1,182
Total Revenue	2,226	1,969	1,732
Operating Revenue	2,226	1,969	1,732
Total Cost of Revenue	631	612	550
Operating Cost of Revenue	631	612	550
Total Operating Expenses	1,484	1,309	1,333
Selling, General & Admin Expense	1,435	1,289	1,131
Restructuring Charge	48	20	202
Total Other Income / (Expense), net	-22	-22	-23
Interest Expense	13	26	26
Other Income / (Expense), net	-8.38	3.87	2.94
Income Tax Expense	-16	18	-28
Basic Earnings per Share	$2.10	$0.17	($2.95)
Weighted Average Basic Shares Outstanding	50.00M	49.71M	49.66M
Diluted Earnings per Share	$2.07	$0.17	($2.95)
Weighted Average Diluted Shares Outstanding	50.53M	49.86M	49.66M
Weighted Average Basic & Diluted Shares Outstanding	49.46M	49.42M	49.72M

This table shows Nu Skin Enterprises' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-25	57	11	27	-37	7.28	-0.53	-118	8.30	-36
Consolidated Net Income / (Loss)	-25	57	11	27	-37	7.28	-0.53	-118	8.30	-36
Net Income / (Loss) Continuing Operations	-25	57	11	27	-37	7.28	-0.53	-118	8.30	-36
Total Pre-Tax Income	-29	24	15	37	-34	9.33	1.10	-132	13	-58
Total Operating Income	-20	27	16	43	-26	16	8.82	-126	18	-53
Total Gross Profit	364	375	348	365	292	352	294	307	301	279
Total Revenue	538	522	481	500	499	489	417	439	430	446
Operating Revenue	538	522	481	500	499	489	417	439	430	446
Total Cost of Revenue	174	148	134	136	207	136	123	132	129	166
Operating Cost of Revenue	174	148	134	136	207	136	123	132	129	166
Total Operating Expenses	385	347	332	322	319	336	285	433	283	332
Selling, General & Admin Expense	354	329	322	322	319	326	278	283	283	286
Restructuring Charge	30	18	9.79	0.00	0.00	10	7.13	149	0.00	46
Total Other Income / (Expense), net	-8.68	-3.10	-1.48	-5.39	-8.09	-6.74	-7.72	-6.09	-4.93	-4.72
Interest Expense	-	-	4.89	5.77	7.54	7.37	7.33	6.72	6.50	5.86
Other Income / (Expense), net	-8.68	10	3.41	0.38	-0.55	0.63	-0.40	0.63	1.57	1.14
Income Tax Expense	-3.57	-33	3.21	10	2.50	2.05	1.63	-13	5.00	-22
Basic Earnings per Share	($0.51)	$1.16	$0.23	$0.54	($0.74)	$0.14	($0.01)	($2.38)	$0.17	($0.73)
Weighted Average Basic Shares Outstanding	50.20M	50.00M	49.64M	49.93M	49.86M	49.71M	49.54M	49.69M	49.71M	49.66M
Diluted Earnings per Share	($0.51)	$1.15	$0.23	$0.54	($0.74)	$0.14	($0.01)	($2.38)	$0.17	($0.73)
Weighted Average Diluted Shares Outstanding	50.20M	50.53M	50.06M	50.16M	49.86M	49.86M	49.54M	49.69M	49.73M	49.66M
Weighted Average Basic & Diluted Shares Outstanding	49.42M	49.46M	49.91M	49.96M	49.41M	49.42M	49.67M	49.70M	49.71M	49.72M

This table details how cash moves in and out of Nu Skin Enterprises' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-75	-8.67	-69
Net Cash From Operating Activities	108	119	112
Net Cash From Continuing Operating Activities	108	119	112
Net Income / (Loss) Continuing Operations	105	8.60	-147
Consolidated Net Income / (Loss)	105	8.60	-147
Depreciation Expense	73	71	70
Non-Cash Adjustments To Reconcile Net Income	118	139	272
Changes in Operating Assets and Liabilities, net	-188	-100	-84
Net Cash From Investing Activities	-67	-135	-38
Net Cash From Continuing Investing Activities	-67	-135	-38
Purchase of Property, Plant & Equipment	-59	-58	-42
Acquisitions	0.00	-77	0.00
Purchase of Investments	-14	-17	-15
Sale and/or Maturity of Investments	5.93	18	18
Net Cash From Financing Activities	-100	11	-133
Net Cash From Continuing Financing Activities	-100	11	-133
Repayment of Debt	-438	-13	-128
Repurchase of Common Equity	-70	-13	0.00
Payment of Dividends	-77	-78	-12
Issuance of Debt	460	110	15
Other Financing Activities, net	25	4.56	-8.36
Effect of Exchange Rate Changes	-16	-3.54	-9.78

This table details how cash moves in and out of Nu Skin Enterprises' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-70	-29	-35	5.61	-2.24	23	-44	12	3.50	-41
Net Cash From Operating Activities	28	26	-22	36	51	54	3.32	51	31	26
Net Cash From Continuing Operating Activities	28	26	-22	36	51	54	3.32	51	31	26
Net Income / (Loss) Continuing Operations	-25	57	11	27	-37	7.28	-0.53	-118	8.30	-36
Consolidated Net Income / (Loss)	-25	57	11	27	-37	7.28	-0.53	-118	8.30	-36
Depreciation Expense	18	19	17	17	18	19	18	18	17	16
Non-Cash Adjustments To Reconcile Net Income	65	20	14	26	83	17	16	160	14	83
Changes in Operating Assets and Liabilities, net	-29	-71	-64	-34	-13	11	-31	-7.66	-7.96	-38
Net Cash From Investing Activities	-25	-13	-15	-93	-12	-15	-9.26	-8.53	-6.55	-14
Net Cash From Continuing Investing Activities	-25	-13	-15	-93	-12	-15	-9.26	-8.53	-6.55	-14
Purchase of Property, Plant & Equipment	-25	-14	-11	-15	-12	-20	-12	-8.12	-8.60	-13
Purchase of Investments	-	-	-8.20	-8.69	-	-	0.00	-8.57	-5.15	-1.04
Net Cash From Financing Activities	-61	-51	1.38	68	-38	-20	-32	-29	-29	-44
Net Cash From Continuing Financing Activities	-61	-51	1.38	68	-38	-20	-32	-29	-29	-44
Repayment of Debt	-2.50	-23	-2.50	-4.05	-3.45	-3.20	-20	-25	-40	-43
Payment of Dividends	-19	-19	-19	-19	-19	-19	-2.98	-2.98	-2.98	-2.98
Other Financing Activities, net	0.72	0.74	3.27	1.51	-2.42	2.20	-8.98	-0.84	-0.80	2.24
Effect of Exchange Rate Changes	-12	9.24	-	-	-2.99	4.24	-	-	7.39	-9.41

This table presents Nu Skin Enterprises' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	1,821	1,809	1,469
Total Current Assets	760	702	539
Cash & Equivalents	265	256	187
Short-Term Investments	14	12	11
Accounts Receivable	47	59	51
Inventories, net	346	280	190
Prepaid Expenses	88	81	73
Other Current Nonoperating Assets	-	14	27
Plant, Property, & Equipment, net	445	433	380
Total Noncurrent Assets	616	674	551
Goodwill	206	218	84
Intangible Assets	67	95	74
Other Noncurrent Operating Assets	343	338	371
Other Noncurrent Nonoperating Assets	-	23	22
Total Liabilities & Shareholders' Equity	1,821	1,809	1,469
Total Liabilities	924	987	817
Total Current Liabilities	359	329	297
Short-Term Debt	25	25	30
Accounts Payable	54	43	35
Accrued Expenses	280	254	218
Other Current Nonoperating Liabilities	-	7.06	14
Total Noncurrent Liabilities	564	658	521
Long-Term Debt	377	478	364
Other Noncurrent Operating Liabilities	187	178	156
Other Noncurrent Nonoperating Liabilities	-	2.16	1.33
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	897	822	651
Total Preferred & Common Equity	897	822	651
Total Common Equity	897	822	651
Common Stock	613	622	628
Retained Earnings	1,939	1,870	1,712
Treasury Stock	-1,569	-1,570	-1,564
Accumulated Other Comprehensive Income / (Loss)	-87	-100	-125

This table presents Nu Skin Enterprises' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	1,763	1,825	1,894	1,793	1,742	1,586	1,583
Total Current Assets	778	774	793	701	647	654	653
Cash & Equivalents	294	230	236	233	213	224	228
Short-Term Investments	14	17	17	17	8.67	8.67	10
Accounts Receivable	48	60	67	77	67	72	69
Inventories, net	327	367	372	291	265	244	248
Prepaid Expenses	94	100	101	83	94	106	99
Plant, Property, & Equipment, net	433	438	430	429	423	412	411
Total Noncurrent Assets	552	613	671	663	672	520	519
Goodwill	206	206	229	229	231	100	100
Intangible Assets	69	65	113	109	102	88	85
Other Noncurrent Operating Assets	277	342	329	325	339	331	334
Total Liabilities & Shareholders' Equity	1,763	1,825	1,894	1,793	1,742	1,586	1,583
Total Liabilities	921	932	998	971	932	900	876
Total Current Liabilities	366	373	445	434	309	309	339
Short-Term Debt	43	48	140	140	30	30	60
Accounts Payable	42	49	50	49	32	36	33
Accrued Expenses	281	276	256	245	247	242	247
Total Noncurrent Liabilities	556	559	553	537	622	591	537
Long-Term Debt	382	373	368	363	453	428	373
Other Noncurrent Operating Liabilities	173	186	186	174	169	163	163
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	842	893	895	822	810	686	707
Total Preferred & Common Equity	842	893	895	822	810	686	707
Total Common Equity	842	893	895	822	810	686	707
Common Stock	610	612	616	619	619	622	625
Retained Earnings	1,901	1,931	1,939	1,882	1,867	1,746	1,751
Treasury Stock	-1,560	-1,559	-1,558	-1,571	-1,565	-1,564	-1,564
Accumulated Other Comprehensive Income / (Loss)	-109	-91	-101	-109	-111	-117	-105

This table displays calculated financial ratios and metrics derived from Nu Skin Enterprises' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	-17.44%	-11.53%	-12.04%
EBITDA Growth	-43.34%	-29.67%	-164.06%
EBIT Growth	-55.92%	-49.12%	-385.09%
NOPAT Growth	-11.94%	-88.04%	-779.78%
Net Income Growth	-28.85%	-91.80%	-1,805.57%
EPS Growth	-27.62%	-91.79%	-1,835.29%
Operating Cash Flow Growth	-23.68%	9.79%	-5.81%
Free Cash Flow Firm Growth	120.25%	-82.96%	1,384.93%
Invested Capital Growth	9.31%	0.80%	-21.01%
Revenue Q/Q Growth	-6.36%	-1.68%	-2.43%
EBITDA Q/Q Growth	12.56%	-5.85%	-134.46%
EBIT Q/Q Growth	23.38%	-12.81%	-40.80%
NOPAT Q/Q Growth	172.72%	-81.40%	-83.87%
Net Income Q/Q Growth	173.34%	-85.31%	-42.04%
EPS Q/Q Growth	176.00%	-85.59%	-41.83%
Operating Cash Flow Q/Q Growth	-43.73%	31.83%	-20.25%
Free Cash Flow Firm Q/Q Growth	-61.33%	122.89%	-4.10%
Invested Capital Q/Q Growth	6.52%	-4.25%	-9.90%
Profitability Metrics	-	-	-
Gross Margin	71.65%	68.93%	68.23%
EBITDA Margin	7.86%	6.25%	-4.55%
Operating Margin	4.98%	2.45%	-8.75%
EBIT Margin	4.60%	2.65%	-8.58%
Profit (Net Income) Margin	4.71%	0.44%	-8.46%
Tax Burden Percent	117.77%	32.34%	83.74%
Interest Burden Percent	86.83%	50.98%	117.77%
Effective Tax Rate	-17.77%	67.66%	0.00%
Return on Invested Capital (ROIC)	13.35%	1.52%	-11.52%
ROIC Less NNEP Spread (ROIC-NNEP)	-22.08%	-2.71%	-33.45%
Return on Net Nonoperating Assets (RNNOA)	-1.77%	-0.52%	-8.38%
Return on Equity (ROE)	11.58%	1.00%	-19.90%
Cash Return on Invested Capital (CROIC)	4.45%	0.72%	11.96%
Operating Return on Assets (OROA)	5.50%	2.87%	-9.07%
Return on Assets (ROA)	5.62%	0.47%	-8.95%
Return on Common Equity (ROCE)	11.58%	1.00%	-19.90%
Return on Equity Simple (ROE_SIMPLE)	11.68%	1.05%	-22.50%
Net Operating Profit after Tax (NOPAT)	131	16	-106
NOPAT Margin	5.87%	0.79%	-6.13%
Net Nonoperating Expense Percent (NNEP)	35.43%	4.23%	21.93%
Return On Investment Capital (ROIC_SIMPLE)	10.04%	1.18%	-10.15%
Cost of Revenue to Revenue	28.35%	31.07%	31.77%
SG&A Expenses to Revenue	64.49%	65.47%	65.30%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	66.67%	66.48%	76.98%
Earnings before Interest and Taxes (EBIT)	102	52	-149
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	175	123	-79
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.13	1.14	0.53
Price to Tangible Book Value (P/TBV)	3.07	1.84	0.69
Price to Revenue (P/Rev)	0.86	0.48	0.20
Price to Earnings (P/E)	18.28	109.01	0.00
Dividend Yield	3.97%	8.23%	3.48%
Earnings Yield	5.47%	0.92%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.00	1.14	0.66
Enterprise Value to Revenue (EV/Rev)	0.92	0.60	0.31
Enterprise Value to EBITDA (EV/EBITDA)	11.66	9.53	0.00
Enterprise Value to EBIT (EV/EBIT)	19.90	22.48	0.00
Enterprise Value to NOPAT (EV/NOPAT)	15.62	75.10	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	18.87	9.88	4.82
Enterprise Value to Free Cash Flow (EV/FCFF)	46.85	158.02	4.89
Leverage & Solvency	-	-	-
Debt to Equity	0.45	0.61	0.60
Long-Term Debt to Equity	0.42	0.58	0.56
Financial Leverage	0.08	0.19	0.25
Leverage Ratio	2.06	2.11	2.22
Compound Leverage Factor	1.79	1.08	2.62
Debt to Total Capital	30.96%	37.97%	37.66%
Short-Term Debt to Total Capital	1.92%	1.89%	2.87%
Long-Term Debt to Total Capital	29.04%	36.08%	34.79%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	69.04%	62.03%	62.34%
Debt to EBITDA	2.30	4.09	-4.99
Net Debt to EBITDA	0.71	1.91	-2.48
Long-Term Debt to EBITDA	2.16	3.88	-4.61
Debt to NOPAT	3.08	32.23	-3.71
Net Debt to NOPAT	0.95	15.07	-1.84
Long-Term Debt to NOPAT	2.89	30.63	-3.43
Altman Z-Score	4.41	3.45	2.93
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	2.12	2.13	1.82
Quick Ratio	0.91	0.99	0.84
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	44	7.42	110
Operating Cash Flow to CapEx	182.98%	202.84%	268.72%
Free Cash Flow to Firm to Interest Expense	3.23	0.29	4.17
Operating Cash Flow to Interest Expense	8.01	4.64	4.23
Operating Cash Flow Less CapEx to Interest Expense	3.63	2.35	2.66
Efficiency Ratios	-	-	-
Asset Turnover	1.19	1.09	1.06
Accounts Receivable Turnover	50.21	37.13	31.64
Inventory Turnover	1.69	1.95	2.34
Fixed Asset Turnover	4.95	4.49	4.26
Accounts Payable Turnover	12.14	12.61	14.11
Days Sales Outstanding (DSO)	7.27	9.83	11.54
Days Inventory Outstanding (DIO)	215.82	186.77	155.96
Days Payable Outstanding (DPO)	30.07	28.96	25.87
Cash Conversion Cycle (CCC)	193.02	167.64	141.63
Capital & Investment Metrics	-	-	-
Invested Capital	1,021	1,029	813
Invested Capital Turnover	2.28	1.92	1.88
Increase / (Decrease) in Invested Capital	87	8.19	-216
Enterprise Value (EV)	2,039	1,172	538
Market Capitalization	1,915	937	343
Book Value per Share	$18.16	$16.64	$13.10
Tangible Book Value per Share	$12.63	$10.29	$9.93
Total Capital	1,300	1,325	1,045
Total Debt	402	503	394
Total Long-Term Debt	377	478	364
Net Debt	124	235	196
Capital Expenditures (CapEx)	59	58	42
Debt-free, Cash-free Net Working Capital (DFCFNWC)	147	130	74
Debt-free Net Working Capital (DFNWC)	426	398	272
Net Working Capital (NWC)	401	373	242
Net Nonoperating Expense (NNE)	26	7.01	40
Net Nonoperating Obligations (NNO)	124	207	162
Total Depreciation and Amortization (D&A)	73	71	70
Debt-free, Cash-free Net Working Capital to Revenue	6.61%	6.61%	4.27%
Debt-free Net Working Capital to Revenue	19.12%	20.21%	15.70%
Net Working Capital to Revenue	18.00%	18.94%	13.97%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$2.10	$0.17	($2.95)
Adjusted Weighted Average Basic Shares Outstanding	50.00M	49.71M	49.66M
Adjusted Diluted Earnings per Share	$2.07	$0.17	($2.95)
Adjusted Weighted Average Diluted Shares Outstanding	50.53M	49.86M	49.66M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	49.46M	49.42M	49.72M
Normalized Net Operating Profit after Tax (NOPAT)	112	48	36
Normalized NOPAT Margin	5.01%	2.42%	2.05%
Pre Tax Income Margin	4.00%	1.35%	-10.11%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	7.59	2.04	-5.63
NOPAT to Interest Expense	9.67	0.61	-4.02
EBIT Less CapEx to Interest Expense	3.22	-0.25	-7.20
NOPAT Less CapEx to Interest Expense	5.30	-1.68	-5.59
Payout Ratios	-	-	-
Dividend Payout Ratio	73.50%	903.11%	-8.14%
Augmented Payout Ratio	140.35%	1,054.49%	-8.14%

This table displays calculated financial ratios and metrics derived from Nu Skin Enterprises' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-16.12%	-22.44%	-20.41%	-10.77%	-7.26%	-6.45%	-13.33%	-12.23%	-13.76%	-8.82%
EBITDA Growth	-112.25%	52.91%	-46.24%	-2.40%	19.17%	-37.47%	-26.32%	-278.74%	525.48%	-200.59%
EBIT Growth	-142.49%	105.31%	-61.58%	-0.01%	7.07%	-55.89%	-56.74%	-391.33%	173.55%	-411.08%
NOPAT Growth	-129.77%	734.01%	-68.55%	-25.12%	-29.98%	-80.56%	-134.09%	-385.36%	161.67%	-396.31%
Net Income Growth	-151.06%	719.81%	-70.62%	-21.45%	-45.55%	-87.27%	-104.69%	-539.75%	122.47%	-595.81%
EPS Growth	-152.58%	776.47%	-69.74%	-19.40%	-45.10%	-87.83%	-104.35%	-540.74%	122.97%	-621.43%
Operating Cash Flow Growth	-5.87%	-76.69%	-392.76%	-23.70%	79.41%	112.21%	115.03%	44.16%	-38.40%	-52.40%
Free Cash Flow Firm Growth	127.50%	83.77%	-39.24%	-491.31%	-367.00%	119.32%	85.20%	213.29%	236.47%	4,018.64%
Invested Capital Growth	-6.32%	9.31%	8.19%	16.66%	12.13%	0.80%	0.55%	-20.79%	-16.05%	-21.01%
Revenue Q/Q Growth	-4.07%	-2.88%	-7.83%	3.90%	-0.30%	-2.03%	-14.60%	5.22%	-2.04%	3.58%
EBITDA Q/Q Growth	-117.54%	622.74%	-15.07%	64.69%	-114.53%	504.40%	55.68%	-499.53%	134.59%	-195.61%
EBIT Q/Q Growth	-167.54%	230.67%	-20.03%	120.18%	-162.77%	162.03%	734.01%	-1,582.65%	115.85%	-362.34%
NOPAT Q/Q Growth	-134.52%	554.31%	-80.58%	145.87%	-159.92%	167.95%	-134.06%	-1,957.94%	112.95%	-426.46%
Net Income Q/Q Growth	-174.16%	325.34%	-80.12%	136.39%	-237.42%	119.71%	-107.32%	-22,087.24%	107.02%	-534.90%
EPS Q/Q Growth	-176.12%	325.49%	-80.00%	134.78%	-237.04%	118.92%	-107.14%	-23,700.00%	107.14%	-529.41%
Operating Cash Flow Q/Q Growth	-38.91%	-10.25%	-186.49%	260.90%	43.65%	6.15%	-93.87%	1,443.31%	-38.62%	-17.97%
Free Cash Flow Firm Q/Q Growth	47.92%	-144.58%	-202.89%	-95.92%	-0.93%	103.23%	56.88%	1,599.66%	21.58%	-2.64%
Invested Capital Q/Q Growth	-2.80%	6.52%	4.42%	7.92%	-6.58%	-4.25%	1.42%	-14.98%	-0.99%	-9.90%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	67.74%	71.70%	72.25%	72.91%	58.60%	72.12%	70.47%	69.96%	70.08%	62.65%
EBITDA Margin	-2.01%	10.80%	7.57%	12.00%	-1.75%	7.22%	6.44%	-24.44%	8.63%	-7.97%
Operating Margin	-3.77%	5.26%	3.34%	8.50%	-5.29%	3.29%	2.11%	-28.60%	4.24%	-11.91%
EBIT Margin	-5.39%	7.25%	4.05%	8.57%	-5.40%	3.42%	2.02%	-28.45%	4.60%	-11.66%
Profit (Net Income) Margin	-4.72%	10.95%	2.36%	5.38%	-7.41%	1.49%	-0.13%	-26.93%	1.93%	-8.10%
Tax Burden Percent	87.66%	234.92%	77.98%	72.46%	107.27%	78.07%	-48.41%	89.83%	62.43%	62.46%
Interest Burden Percent	100.00%	64.35%	74.90%	86.55%	127.99%	55.87%	13.07%	105.38%	67.17%	111.29%
Effective Tax Rate	0.00%	-134.92%	22.02%	27.54%	0.00%	21.93%	148.41%	0.00%	37.57%	0.00%
Return on Invested Capital (ROIC)	-6.33%	28.11%	5.33%	11.76%	-7.29%	4.93%	-1.82%	-35.79%	4.75%	-15.68%
ROIC Less NNEP Spread (ROIC-NNEP)	-17.32%	18.08%	4.31%	9.17%	-17.29%	1.76%	-0.11%	-48.42%	3.38%	-15.11%
Return on Net Nonoperating Assets (RNNOA)	-1.98%	1.45%	0.53%	1.50%	-3.84%	0.34%	-0.03%	-14.72%	0.99%	-3.79%
Return on Equity (ROE)	-8.32%	29.56%	5.86%	13.27%	-11.13%	5.27%	-1.85%	-50.51%	5.74%	-19.46%
Cash Return on Invested Capital (CROIC)	11.36%	4.45%	2.81%	-6.22%	-3.19%	0.72%	-1.52%	14.57%	11.62%	11.96%
Operating Return on Assets (OROA)	-6.85%	8.65%	4.58%	9.22%	-6.08%	3.71%	2.16%	-30.15%	4.84%	-12.32%
Return on Assets (ROA)	-6.00%	13.08%	2.67%	5.79%	-8.35%	1.62%	-0.14%	-28.54%	2.03%	-8.56%
Return on Common Equity (ROCE)	-8.32%	29.56%	5.86%	13.27%	-11.13%	5.27%	-1.85%	-50.51%	5.74%	-19.46%
Return on Equity Simple (ROE_SIMPLE)	4.55%	0.00%	8.67%	7.83%	7.12%	0.00%	-0.41%	-21.64%	-14.60%	0.00%
Net Operating Profit after Tax (NOPAT)	-14	65	13	31	-18	13	-4.27	-88	11	-37
NOPAT Margin	-2.64%	12.35%	2.60%	6.16%	-3.70%	2.57%	-1.02%	-20.02%	2.65%	-8.34%
Net Nonoperating Expense Percent (NNEP)	10.98%	10.03%	1.02%	2.60%	10.01%	3.17%	-1.72%	12.63%	1.37%	-0.57%
Return On Investment Capital (ROIC_SIMPLE)	-	4.96%	-	-	-	0.95%	-	-	-	-3.56%
Cost of Revenue to Revenue	32.26%	28.30%	27.75%	27.09%	41.40%	27.88%	29.53%	30.04%	29.92%	37.35%
SG&A Expenses to Revenue	65.91%	62.93%	66.88%	64.41%	63.88%	66.79%	66.64%	64.54%	65.85%	64.27%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	71.51%	66.44%	68.92%	64.41%	63.88%	68.84%	68.35%	98.55%	65.85%	74.57%
Earnings before Interest and Taxes (EBIT)	-29	38	19	43	-27	17	8.43	-125	20	-52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-11	56	36	60	-8.72	35	27	-107	37	-35
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.84	2.13	2.05	1.76	1.24	1.14	0.84	0.76	0.52	0.53
Price to Tangible Book Value (P/TBV)	2.74	3.07	2.94	2.85	2.11	1.84	1.42	1.05	0.70	0.69
Price to Revenue (P/Rev)	0.65	0.86	0.87	0.77	0.51	0.48	0.36	0.28	0.21	0.20
Price to Earnings (P/E)	40.50	18.28	23.64	22.51	17.41	109.01	0.00	0.00	0.00	0.00
Dividend Yield	4.98%	3.97%	4.17%	4.90%	7.62%	8.23%	8.93%	8.54%	7.73%	3.48%
Earnings Yield	2.47%	5.47%	4.23%	4.44%	5.74%	0.92%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.74	2.00	1.88	1.59	1.18	1.14	0.88	0.82	0.62	0.66
Enterprise Value to Revenue (EV/Rev)	0.70	0.92	0.95	0.90	0.64	0.60	0.49	0.41	0.32	0.31
Enterprise Value to EBITDA (EV/EBITDA)	10.74	11.66	15.40	14.25	9.73	9.53	10.72	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	20.10	19.90	34.70	31.74	21.27	22.48	60.68	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	34.87	15.62	18.30	18.73	15.16	75.10	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	8.69	18.87	25.54	27.19	14.14	9.88	6.54	4.69	4.01	4.82
Enterprise Value to Free Cash Flow (EV/FCFF)	14.83	46.85	69.53	0.00	0.00	158.02	0.00	4.98	4.89	4.89
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.50	0.45	0.47	0.57	0.61	0.61	0.60	0.67	0.61	0.60
Long-Term Debt to Equity	0.45	0.42	0.42	0.41	0.44	0.58	0.56	0.62	0.53	0.56
Financial Leverage	0.11	0.08	0.12	0.16	0.22	0.19	0.26	0.30	0.29	0.25
Leverage Ratio	2.10	2.06	2.03	2.07	2.14	2.11	2.09	2.20	2.21	2.22
Compound Leverage Factor	2.10	1.33	1.52	1.79	2.74	1.18	0.27	2.32	1.48	2.48
Debt to Total Capital	33.54%	30.96%	31.99%	36.19%	37.95%	37.97%	37.36%	40.05%	38.01%	37.66%
Short-Term Debt to Total Capital	3.36%	1.92%	3.62%	9.98%	10.57%	1.89%	2.32%	2.62%	5.26%	2.87%
Long-Term Debt to Total Capital	30.18%	29.04%	28.38%	26.21%	27.39%	36.08%	35.04%	37.43%	32.75%	34.79%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	66.46%	69.04%	68.01%	63.81%	62.05%	62.03%	62.64%	59.95%	61.99%	62.34%
Debt to EBITDA	2.73	2.30	3.23	3.95	3.85	4.09	5.50	-5.77	-12.89	-4.99
Net Debt to EBITDA	0.75	0.71	1.33	1.99	1.93	1.91	2.98	-2.84	-5.82	-2.48
Long-Term Debt to EBITDA	2.46	2.16	2.86	2.86	2.78	3.88	5.16	-5.39	-11.11	-4.61
Debt to NOPAT	8.88	3.08	3.84	5.19	5.99	32.23	-46.52	-5.15	-7.51	-3.71
Net Debt to NOPAT	2.44	0.95	1.58	2.61	3.01	15.07	-25.22	-2.53	-3.39	-1.84
Long-Term Debt to NOPAT	7.99	2.89	3.40	3.76	4.32	30.63	-43.64	-4.82	-6.47	-3.43
Altman Z-Score	4.10	4.29	4.11	3.75	3.35	3.38	3.28	3.05	3.20	3.14
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.13	2.12	2.08	1.78	1.62	2.13	2.09	2.12	1.93	1.82
Quick Ratio	0.97	0.91	0.82	0.72	0.75	0.99	0.93	0.99	0.90	0.84
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	50	-23	-68	-134	-135	4.35	-10	151	184	179
Operating Cash Flow to CapEx	111.73%	185.21%	-192.19%	241.45%	428.58%	265.72%	27.02%	630.40%	365.66%	204.92%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-13.95	-23.15	-17.89	0.59	-1.38	22.52	28.30	30.54
Operating Cash Flow to Interest Expense	0.00	0.00	-4.52	6.16	6.77	7.35	0.45	7.62	4.84	4.40
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-6.87	3.61	5.19	4.59	-1.22	6.41	3.51	2.25
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.27	1.19	1.13	1.08	1.13	1.09	1.07	1.06	1.05	1.06
Accounts Receivable Turnover	47.33	50.21	37.48	36.84	31.98	37.13	29.99	26.58	24.31	31.64
Inventory Turnover	1.77	1.69	1.61	1.63	2.02	1.95	1.90	1.94	1.93	2.34
Fixed Asset Turnover	5.30	4.95	4.74	4.68	4.65	4.49	4.43	4.38	4.23	4.26
Accounts Payable Turnover	14.03	12.14	13.37	11.30	13.82	12.61	14.72	13.93	12.79	14.11
Days Sales Outstanding (DSO)	7.71	7.27	9.74	9.91	11.41	9.83	12.17	13.73	15.02	11.54
Days Inventory Outstanding (DIO)	206.34	215.82	226.42	224.54	181.08	186.77	191.64	188.11	189.11	155.96
Days Payable Outstanding (DPO)	26.02	30.07	27.30	32.31	26.40	28.96	24.80	26.20	28.54	25.87
Cash Conversion Cycle (CCC)	188.04	193.02	208.86	202.14	166.08	167.64	179.02	175.64	175.59	141.63
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	959	1,021	1,066	1,151	1,075	1,029	1,072	912	903	813
Invested Capital Turnover	2.40	2.28	2.05	1.91	1.97	1.92	1.78	1.79	1.80	1.88
Increase / (Decrease) in Invested Capital	-65	87	81	164	116	8.19	5.82	-239	-173	-216
Enterprise Value (EV)	1,669	2,039	2,004	1,833	1,272	1,172	942	749	562	538
Market Capitalization	1,552	1,915	1,830	1,577	1,019	937	680	523	366	343
Book Value per Share	$16.71	$18.16	$18.05	$17.94	$16.46	$16.64	$16.36	$13.82	$14.22	$13.10
Tangible Book Value per Share	$11.25	$12.63	$12.57	$11.09	$9.68	$10.29	$9.64	$10.02	$10.50	$9.93
Total Capital	1,267	1,300	1,313	1,403	1,325	1,325	1,293	1,144	1,140	1,045
Total Debt	425	402	420	508	503	503	483	458	433	394
Total Long-Term Debt	382	377	373	368	363	478	453	428	373	364
Net Debt	117	124	173	255	253	235	262	225	196	196
Capital Expenditures (CapEx)	25	14	11	15	12	20	12	8.12	8.60	13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	147	147	202	235	157	130	147	143	136	74
Debt-free Net Working Capital (DFNWC)	455	426	448	488	407	398	368	376	374	272
Net Working Capital (NWC)	412	401	401	348	267	373	338	346	314	242
Net Nonoperating Expense (NNE)	11	7.29	1.15	3.91	18	5.26	-3.74	30	3.08	-1.05
Net Nonoperating Obligations (NNO)	117	124	173	255	253	207	262	225	196	162
Total Depreciation and Amortization (D&A)	18	19	17	17	18	19	18	18	17	16
Debt-free, Cash-free Net Working Capital to Revenue	6.18%	6.61%	9.59%	11.52%	7.84%	6.61%	7.70%	7.75%	7.67%	4.27%
Debt-free Net Working Capital to Revenue	19.14%	19.12%	21.32%	23.88%	20.33%	20.21%	19.32%	20.38%	21.07%	15.70%
Net Working Capital to Revenue	17.35%	18.00%	19.07%	17.02%	13.34%	18.94%	17.74%	18.76%	17.69%	13.97%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.51)	$1.16	$0.23	$0.54	($0.74)	$0.14	($0.01)	($2.38)	$0.17	($0.73)
Adjusted Weighted Average Basic Shares Outstanding	50.20M	50.00M	49.64M	49.93M	49.86M	49.71M	49.54M	49.69M	49.71M	49.66M
Adjusted Diluted Earnings per Share	($0.51)	$1.15	$0.23	$0.54	($0.74)	$0.14	($0.01)	($2.38)	$0.17	($0.73)
Adjusted Weighted Average Diluted Shares Outstanding	50.20M	50.53M	50.06M	50.16M	49.86M	49.86M	49.54M	49.69M	49.73M	49.66M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	49.42M	49.46M	49.91M	49.96M	49.41M	49.42M	49.67M	49.70M	49.71M	49.72M
Normalized Net Operating Profit after Tax (NOPAT)	6.89	32	20	31	-18	20	11	17	11	-5.04
Normalized NOPAT Margin	1.28%	6.14%	4.19%	6.16%	-3.70%	4.16%	2.68%	3.79%	2.65%	-1.13%
Pre Tax Income Margin	-5.39%	4.66%	3.03%	7.42%	-6.91%	1.91%	0.26%	-29.98%	3.09%	-12.97%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	3.98	7.43	-3.57	2.27	1.15	-18.59	3.05	-8.86
NOPAT to Interest Expense	0.00	0.00	2.56	5.34	-2.45	1.70	-0.58	-13.08	1.75	-6.34
EBIT Less CapEx to Interest Expense	0.00	0.00	1.63	4.88	-5.15	-0.50	-0.53	-19.80	1.72	-11.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.21	2.79	-4.03	-1.06	-2.26	-14.29	0.43	-8.48
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	200.68%	73.50%	99.58%	110.14%	132.21%	903.11%	-1,846.98%	-30.12%	-27.34%	-8.14%
Augmented Payout Ratio	383.41%	140.35%	99.58%	110.14%	171.54%	1,054.49%	-1,846.98%	-30.12%	-27.34%	-8.14%

Financials Breakdown Chart

Nu Skin Enterprises Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Nu Skin Enterprises' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

Nu Skin Enterprises' net income appears to be on an upward trend, with a most recent value of -$146.59 million in 2024, falling from $104.78 million in 2022. The previous period was $8.60 million in 2023. See Nu Skin Enterprises' forecast for analyst expectations on what's next for the company.

Nu Skin Enterprises' total operating income in 2024 was -$151.59 million, based on the following breakdown:

Total Gross Profit: $1.18 billion
Total Operating Expenses: $1.33 billion

Over the last 2 years, Nu Skin Enterprises' total revenue changed from $2.23 billion in 2022 to $1.73 billion in 2024, a change of -22.2%.

Nu Skin Enterprises' total liabilities were at $817.46 million at the end of 2024, a 17.1% decrease from 2023, and a 11.5% decrease since 2022.

In the past 2 years, Nu Skin Enterprises' cash and equivalents has ranged from $186.88 million in 2024 to $264.73 million in 2022, and is currently $186.88 million as of their latest financial filing in 2024.

Over the last 2 years, Nu Skin Enterprises' book value per share changed from 18.16 in 2022 to 13.10 in 2024, a change of -27.8%.

Related Companies

Financial statements for NYSE:NUS last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nu Skin Enterprises (NUS) Financials

Financials Breakdown Chart

Nu Skin Enterprises Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nu Skin Enterprises (NUS) Financials

Annual Income Statements for Nu Skin Enterprises

Quarterly Income Statements for Nu Skin Enterprises

Annual Cash Flow Statements for Nu Skin Enterprises

Quarterly Cash Flow Statements for Nu Skin Enterprises

Annual Balance Sheets for Nu Skin Enterprises

Quarterly Balance Sheets for Nu Skin Enterprises

Annual Metrics And Ratios for Nu Skin Enterprises

Quarterly Metrics And Ratios for Nu Skin Enterprises

Financials Breakdown Chart

Nu Skin Enterprises Financials - Frequently Asked Questions

When does Nu Skin Enterprises' fiscal year end?

How has Nu Skin Enterprises' net income changed over the last 2 years?

What is Nu Skin Enterprises' operating income?

How has Nu Skin Enterprises' revenue changed over the last 2 years?

How much debt does Nu Skin Enterprises have?

How much cash does Nu Skin Enterprises have?

How has Nu Skin Enterprises' book value per share changed over the last 2 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools